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. HIV/HBV co-infection was highly prevalent in ART-naïve patients. CD4 cell count was lower in patients who were HBsAg positive and our results showed that there was an association between HBV and CD4 cell count. This association was that having HBV increases the risk for CD4<200 at ART initiation. This is consistent with other studies that show that co-infections in HIV patients lead to further reduction of the CD4 count. Having HBV also increased the odds of one experiencing an elevated ALT before ART initiation, suggesting that the observed ALT elevation is due to damage to the hepatocytes by the body.
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In ART-naïve patients, the prevalence of HIV/HBV co-infection was high. HBV was associated with CD4 cell count <200 and elevated ALT at ART initiation. (Lacombe et al., 2005, Hwang and Cheung, 2011) . In Africa 50 million people are chronic HBV carriers. In sub-Saharan Africa, the prevalence of HBV is 6-20 % with a mortality rate of 25% (Martin-Carbonero and Soriano, 2010) . In Zambia, this population is not clearly described due to poor diagnostic capacity, particularly in rural areas where access to testing kits, traditional sample processing, storage and transportation to testing facilities are major challenges.
Zambia, being part of sub-Saharan region, has not been spared of HIV or HBV. According to the 2013/2014 Zambia Demographic Health Survey (ZDHS), approximately 13% of Zambians are currently living with HIV (Central statistics office, 2015) . The prevalence of HBV in Zambia, however, has not been clearly described in either adults or infants. This can be attributed to fewer studies done and also less survey studies done on HBV. The prevalence of HIV and HBV coinfection in Zambia has been described by four different studies conducted within Lusaka. It should be noted that three of these studies have been done at either a single hospital or clinic.
The prevalences have been reported as 7.1% by Oshitani et al (1996 ), 31.1% by Kapembwa et al (2011 ), 14.3% by Harmers et al (2013 and 12.2% by Vinikoor et al (2015) .
Yves Benhamou, a French physician, reported a global estimate of HBV infection in persons
infected with HIV to be approximately 5-10%. Most infections that occur in adults are due to sexual contact and injection drug use (IDU) in most developing countries and chronic infection is between 6-14% in the United States of America (USA) and Western Europe (Benhamou, 2007) .
Effect of HBV on HIV 2.2
There are different reports on the effect of HBV on HIV (Benhamou, 2007) . Some studies have reported that HBV does not affect HIV-related mortality. Other studies suggest that the HBV protein (HBx) increases the rate of HIV replications, thereby making progression faster.
However, this evidence was disputed by a EUROSIDA cohort study that found that HBsAg positivity does not affect progression of HIV (Konopnicki et al., 2005) . Co-infection with hepatitis B virus is common because of the shared routes of transmission (den Brinker et al., 2000) . In adults, the main route of transmission is sexual transmission (Eng-Kiong and Anna, 2013).
HBV is a deoxyribonucleic acid (DNA) virus that affects and replicates in the hepatocytes of the liver. Because of the compromised immune system in HIV-infected individuals, co-infection with HBV can lead to the development of symptomatic acute HBV infection, which can easily progress into chronic infections. It has been reported that HIV-infected individuals tend to lose their developed protective anti-Hepatitis B virus surface antigen (anti-HBsAg) (Biggar et al., 1987) . Because of the compromised immune system, the body fails to fight off the infection and it progresses from acute infection to chronic infection.
The CD4 and CD8 cells play an important role in HIV infected patients by controlling viral replication. Some researchers suggest that the earlier treatment is initiated in HBV co-infected patients, the better the response to viral suppression both for HBV and HIV. Some researchers have reported that immune reconstitution during cART is achieved but the HIV-specific CD4 T cell responses are rarely recovered (Olawumi et al., 2014) . With the wide distribution of ARVs, it is now evident that more people are accessing combined antiretroviral therapy (cART) and as a result, HIV-related morbidity and mortality has greatly declined (Thio, 2009 , Sulkowski et al., 2002 .
Another effect that HBV has is directly on the function of the liver. One of the tests used to estimate liver function is Alanine transferase (ALT). This is an enzyme that is normally found inside the liver cells. When it is found in high quantities in the blood, it means that this enzyme has been released from the liver by destruction of hepatocytes (Pratt and Kaplan, 2000) .
However, there are certain factors known to increase the enzyme levels in the serum and these include: alcohol, lipid lowering drugs, antibiotics, co-infection with HBV, hepatic damage caused by HIV and type of regimen. In co-infected patients, progression of liver damage to cirrhosis can be accelerated. In HIV positive patients, high ALT levels can be due to a number of factors including high or uncontrolled HIV RNA levels, high body mass index (BMI), and increase in age and prolonged use of ARVs. In HIV/HBV co-infected patients, high levels of ALT can be associated with acute infection of HBV. According to the 2010 Ministry of Health treatment guidelines, elevated ALT was described as greater than times two upper limit of normal (Ministry of Health., 2010) . A high ALT level at initiation of ART is usually an indication of possible future ALT elevations (Crane et al., 2010) . ALT levels can also be elevated when HBV replication is not controlled as the hepatocytes infected with HBV can be destroyed by the cell mediated immune system. As the body tries to kill or eliminate the virus, the liver cells are also destroyed in the process.
ALT estimate is an inexpensive routine test that is non-invasive but a reliable means of assessing liver disease in patients suffering from hepatic viral diseases. This is because in most instances, it reflects the activity of the hepatotoxic viruses and the state of the liver. ALT is usually measured before initiation of ART in order to estimate how well the liver is functioning. When it is elevated at this stage, it gives an indication that the liver is compromised. In such instances, drugs that are hepatotoxic are by all means avoided so that further damage to the liver that can compromise its functions is avoided.
A number of studies have shown that HBV can infect the hepatocytes. In a study done in Italy it is suggested that hepatotoxicity occurs significantly more in co-infected patients than in those who are mono-infected (Aceti et al., 2002) . Another study done in South Africa reported that there was an increase of ALT levels in 33.3% of the 21 HIV/HBV co-infected patients at the onset of treatment (Ayuk et al., 2013) . A cohort study conducted at the University of Amsterdam which studied patients mono-infected with HIV, co-infected with HIV/HBV or co-infected with HIV/HCV, observed that patients co-infected with chronic viral hepatitis were more likely to have elevated liver enzymes. The incidence of elevated liver enzyme was 33% in co-infected patients and 12% in mono-infected patients (den Brinker et al., 2000) .
Risk factors for elevated ALT 2.3
In 2010, a study was done by Kovari et al based on a national cohort program in HIV monoinfected patients on the association of metabolic parameters of chronic elevated ALT. In this study it was observed that a high BMI was significantly associated with chronic elevated ALT.
There was also association of severe alcohol use and incidence of elevated ALT levels. In this study, it was discovered that the main cause of chronic liver disease in HIV mono-infected individuals was alcohol consumption, non-alcoholic fatty liver disease (NAFLD) and ART (Kovari et al., 2010) 
CHAPTER THREE: RESEARCH FOCUS
Statement of the problem 3.1 Zambia has been shown to have a high prevalence of HIV/HBV co-infection (12.2%) (Vinikoor et al., 2015) . More studies on the impact of HIV/HBV on the liver and CD4 cells are needed in order to have a better understanding of these two infections in patients. Some studies have shown that patients infected with HBV are at increased risk of hepatotoxicity and that co-infection may lead to reduced CD4 cell count before cART (Aceti et al., 2002) . Due to the fact that the hepatitis virus survives and replicates in the liver, the immune system targets these liver cells in trying to fight the HBV infection. As a result, ALT is released from these cells as they are being released and as such, an infected person will have higher ALT than normal even before cART is commenced. Some ART drugs have been implicated in hepatotoxicity. If patients with HBV infection that already have elevating the ALT, the increase in ALT is even more. Infection with HIV is associated with decreasing CD4 cells as the virus continues to replicate in the body. In some cases HIV infected patients are also infected with HBV which can be chronic if ones immune system is already compromised. This may lead to even further decrease of CD4 cells in such patients.
It would be important to carry out studies in Zambia in order to evaluate the relationship of HIV/HBV co-infection with CD4 cell count and ALT levels before cART in adult patients.
Research on ALT levels in HIV/HBV co-infected patients is very cardinal as this is one enzyme released by the liver when the hepatocytes are being destroyed in trying to fight infection by the immune system. This enzyme is an indicator of liver damage in the body. Most studies carried out in Zambia have focused on prevalence of HIV/HBV co-infection and not specifically on HIV/HBV being related to CD4 cell count and ALT levels in ART naive patients.
Justification
3.2
There is need to study the relationship of HIV/HBV with CD4 cell count and ALT levels in ART naive patients in Zambia. The Ministry of Health has identified viral hepatitis as a significant public health condition to be addressed in Zambia. This study will show the importance of screening HIV positive patients for viral hepatitis B as it has implications on how the patients respond to anti-retroviral therapy.
There is little or no published data on the relationship of HIV/HBV with CD4 cell count and ALT levels in ART naïve patients in Zambia. This study will include patients that were to be initiated on cART based on the 2010 Ministry of Health treatment guidelines from selected clinics in Lusaka.
Research question
3.3 Is HIV/HBV co-infection related to CD4 cell count and ALT levels in anti-retroviral therapy naïve patients?
General objective 3.4
To determine the prevalence of HIV/HBV co-infection and its relationship with CD4 cell count and ALT levels in ART naive patients. 
Specific objectives
SMART CARE
Patient information in this study was captured using SMART CARE which is a large database and the Laboratory Information Systems (LIMS). The data used in this study was from SMARTCARE database and Laboratory Information Systems (LIMS). The data in SMART CARE was captured as patients attended antiretroviral therapy clinic. The outcome variables in this study were CD4 cell count and ALT levels. CD4 cell count and ALT level were used as categorical outcome variables.
LIMS
Data management and analysis 4.6
Data management and analysis were performed using Stata software, version 12.1 (Stata). Some graphs were constructed using Microsoft Excel. In this cross-sectional study, controls were considered to be those patients that had HIV but tested negative for HBsAg and cases were those that had HIV and tested positive for HBsAg.
The data that was used in this study did not contain any personal unique identifier such as names, patient identity numbers (PID), addresses and phone numbers that are used at the ART clinic but numerical numbers from one were instead used as a replacement. The data obtained was kept confidential and was not shared with anyone else. It was not transferred through internet for any purpose. Data was also be coded for the purpose of data analysis.
Proportions were used to describe the overall prevalence of HIV/HBV co-infection as well as the prevalence by clinic. The prevalence of HBV was defined as the number of those who are HBsAg-positive divided by the total tested (with 95% confidence interval). The Chi-Square test was used to test for associations of categorical variables. For normally distributed continuous variables, associations were tested using t-test and the Ranksum-test was used for non-normal continuous variables.
To answer objectives two and three, associations that were significant from the above tests were included in the uni-variate and multi-variate analysis of the logistic regression models. Using logistic regression models, I assessed the bivariate and multivariate relative risk of the outcome of interest (CD4 and ALT) for potential co-factors. ALT was analysed as a categorical outcome variable for objective two. It was categorised into either elevated or not elevated. Elevated ALT was defined as 2×ULN (66). This was adopted from the MOH 2010 HIV treatment guidelines.
CD4 was also categorized as either less than 200 or greater than or equal to 200.
For multivariate analyses, variables that were not significant after being adjusted for all the other variable in the model were dropped one by one from the full model and were not included in the final nested model. The nested model was tested against the full model using the likelihood ratio test. The variability between the two populations will be explained using the standard deviation (SD) and p-values.
It should be noted that the multivariate analysis did not include all the 5,436 patients due to missing data of some variables. All P-values were 2 sided at P value <0.05.
Missing Data 4.7
Between 2011 and 2013, about 26,775 patients were enrolled into ART care in the 15 clinics that were sampled. Of these, about 19,053 were not screened for HBsAg. Of the 7,722 that were screened for HBsAg, 5,436 had their results recorded as either negative or positive and had a baseline CD4 cell count and ALT result. The other 2,286 had either results recorded as unknown or were missing either missing ALT or CD4 result. Missing other exploratory variables was not ground for exclusion from the study. This was because the sample size would have drastically reduced if all these variables were put into consideration taking into account the small number of co-infected cases included in the study (n=667).
CHAPTER FIVE: RESULTS
Baseline patient characteristics 5.1
In our study population, 12.3% were HBsAg positive. In the overall study population, only about 26% (n=1328) of the study population had indicated as having attained at least a minimum of grade 12 level of education. The median (IQR) age of the entire population was 35 (29-41) years.
When age was categorized into four categories, 18-29, 30-39, 40-60, and >60 , most of the study population was in the category of 30-39 (n=2,346) . There were more females (53.4) in the study population than males. The median CD4 cell count and median ALT with their inter-quatile range were 202 (102) and 20 (14-30) respectively. 
Table1. Characteristics of participants
HIV/HBV Co-infection by clinic 5.2
A total of 5,436 patients were included in the study. Of these, 667 patients were co-infected with HIV and HBV while 4,679 were mono-infected with HIV. In this study, 15 clinics were included: Bauleni, Chawama, Chelstone, Chilenje, Chipata, George, Kabwata, Kalingalinga, Kamwala, Kanyama, Makeni, Matero Main, Matero Reference, Mtendere, and Ngombe. The number of patients that were screened in the stipulated study period varied from clinic to clinic.
The number of patients at the clinics were as low as 1 and as high as 1,191. The lowest prevalence of co-infection was 0%. This was from Makeni clinic which only had one patient, and that patient was mono-infected. The highest prevalence of co-infection was 33.33% and this was from Kabwata clinic which had 3 patients. The 33.33% observed at Kabwata clinic was the highest from the 15 clinics in the study. The rest of the clinics had co-infection prevalences of less than 15%, as indicated in table 2. The median CD4 cell counts were significantly different in the two groups p-value=0.019.
Patients who were mono-infected had a higher median CD4 cell count (median CD4 cell count=204cells/µl) compared to the patients who were co-infected (median CD4 cell count=181cells/µl). About 53.3% (n=357) of co-infected patients had a CD4 cell count of less than 200 at the time of enrollment. The population of those mono-infected with HIV had 48.9%
(n=2,333) with a CD4 cell count of less than 200 cells/µl at enrollment.
There was a statistically significant difference in the median ALT levels in the two study populations with a p-value <0.0001. The median ALT level in the co-infected population was higher (24 IU/ml) with a wider interquartile range (16-41 IU/ml) than the group of those with HIV mono-infection who had a median ALT of 20 IU/ml and a narrower interquartile range (14-29 IU/ml).
The mean haemoglobin in the population of those mono-infected was almost the same as that of the co-infected (11.55 g/dL and 11.42 g/dL respectively). The difference in the two populations was not statistically significant p-value=0.077.The median creatinine levels in the two populations were the same (79 µmol/L). This difference in the two populations was not significant p-value=0.7321.
The difference in the number of the patients who were in the WHO staging of 3and 4 in the two populations was statistically significant p-value=0.011. About 1,830 (49%) Patients were in stage 3 and 4 in the mono-infected group compared to (290) 33.3% in the co-infected group.
There was no statistically significant difference in the median age in the two groups p-value=0.0563. The highest prevalence of co-infection was in the age category of 30-39 (n=319) and was the age category with most patients (48%).
There was a statistically significant difference (p-value=0.023) in the prevalence of active TB in the two populations. Those co-infected had a higher proportion of patients with active TB n=67 (10.0%) compared to those that were mono-infected n=359 (7.5%).
In the chi-square test (Table 3) , it was observed that age, haemoglobin, and creatinine were not associated with HBsAg (p-values 0.0563, 0.0768, and 0.7321 respectively).However, sex, CD4, ALT, BMI, WHO staging, and having active TB were strongly associated with HBsAg, p-values <0.001, 0.026, <0.001, 0.0002, 0.011, and 0.023 respectively.
Variables associated with CD4<200 5.4 Elevated ALT was not associated with CD4<200. As it can be seen in table 4, there was no difference in elevated ALT in the two groups that had a CD4<200 and those that had a CD4≥200. The proportions of those that had elevated ALT were 6% (n=165) in those with a CD4<200 compared to 5% (n=137) in those with a CD4≥200 was not statistically different (p-value=0.065). Because of this, the variable of categorized ALT was left out of the logistic regression.
The variables that were found to be associated with CD4<200 were HBsAg, having active TB, sex, WHO staging, age, BMI, creatinine and haemoglobin (p-values 0.026, <0.001, <0.0001, <0.001, <0.0001, <0.0001, 0.041 and <0.0001 respectively).
Variables associated with elevated ALT 5.5 In the test of association used to investigate which variables are associated with one having an ALT≥66 before ART initiation, it was observed that HBsAg, sex, WHO staging, ceatinine, and haemoglobin were associated with elevated ALT before ART initiation. Having active TB, CD4, creatinine and BMI were not associated with an elevated ALT before ART initiation.
Variables in the univariate and multivariate analysis for CD4 5.6
In the univariate analysis, increasing age (modeled as a continuous variable) was associated with decreased risk of having a CD4<200 before ART initiation. After adjusting for sex, BMI, creatinine, haemoglobin, and WHO staging, in the multivariate analysis, age was still inversely associated with CD4<200 before ART initiation.
Being female was associated with a 37% odds of having a CD4<200 at baseline compared to being males. After adjusting for age, BMI, creatinine, haemoglobin, WHO staging, and HBsAg status, this odds increased by 50%. With every unit increase in BMI, the odds of a patient having CD4<200 increased by 12% (unadjusted estimate). When adjusted for sex, HBsAg, age, creatinine, haemoglobin and WHO staging, the odds of CD4<200 was 6% higher (for every unit increase). Creatinine was less likely to be associated with a CD4<200 before ART initiation.
After adjusting for age, sex, BMI, haemoglobin, HBsAg, and WHO staging. With every unit increase of haemoglobin, there is a 27% change in odds of having a CD4<200 at enrolment. This association was still the same even after adjusting for sex, BMI, creatinine, HBsAg, and WHO staging.
In univariate analysis, Active TB was positively associated with risk of CD4<200, but this association did not remain significant after being adjustment for. Because of this it was removed from the final model used in analyzing risk factors for CD4<200. HBsAg was not significantly associated with having a CD4<200 before ART initiation in the multivariate model but because it was the main exposure of interest, it was included in the final model. Having a WHO staging (3 or 4) was less likely to be a risk for having a CD4<200 before ART initiation. Variables associated with elevated ALT 5.7 Our reported co-infection prevalence falls within the reported prevalence ranges in sub-Saharan Africa of 6-20% (Martin-Carbonero and Soriano, 2010) . Some studies in southern Africa have reported both similar and varying prevalences. However, some of the differences in prevalence can be explained by the difference in study design as well as study settings. It was observed that this co-infection differed greatly from clinic to clinic, ranging from 0% to 33.3 %. This difference can be explained by the fact that some clinics included in the study had only a few patients tested for HBsAg that were included.
HBsAg was found to be related to ALT in the sense that when one is HBsAg positive, the odds of having an elevated ALT before ART initiation was 2.4 times the odds of having an elevated ALT at baseline when one is HBsAg negative. Males were more likely to be co-infected (56.7%) compared to females (43.3%). These findings are similar to what Gupta and Singh found in 2010 when they looked at occult HBV in ART-naïve patients (Swati Gupta, 2010) . Our results are comparable to those reported from other studies showed that patients who were co-infected were more at risk of hepatotoxicity than patients who only had HIV. This study showed that about 11 % of patients who were co-infected had elevated ALT compared to mono-infected patients (4.8%) and this difference was statistically significant (p-value <0.001). Similar studies have shown similar results. For example, a study done by John Idoko et al in 2009 found that the percentage of those with elevated ALT was 16%, which was higher than what we found (John Idoko, 2009) . Some studies suggest that elevated ALT usually occurs in patients who are HBeAg positive, "a serology test that was not available in this study". They mention that some patients still experience elevated ALT even when they are HBsAg negative but the frequency is much lower (27% vs 10%).
Our findings can be explained by the fact that the hepatitis B virus survives and reproduces in the liver cells (hepatocytes). When one is infected with this virus the body fights the infection, either removing the free-moving virus in the blood or by eliminating the hepatocytes that are infected.
In the process, the enzyme ALT is released from the cells and into the blood. This implies that the elevated ALT observed in our study was due to the hepatitis and not the HIV. In our study, we found that WHO staging of 3 or 4 was not a significant risk factor for elevated ALT. One simple explanation could be that the elevated ALT observed was not due to the poor health of patients.
In our study, we found evidence that being co-infected with HIV/HBV was associated with a lower CD4 count. A recent study reported no significant difference in the CD4 cell count at baseline in the two groups (Yang et al, 2014) . We observed that being HBsAg positive was more likely to be associated with one having a CD4 cell count of less than 200. This observation suggests that co-infection will lead to further compromise of the immune system and this would be indicated in the CD4 cell count. This is because the body fights two viruses compared to mono-infected patients who only try to manage one virus. However, it would have been important to have conducted a prospective study that would have allowed for further investigation.
There were a number of limitations to this study, including some inherent in the design itself. As this was a retrospective study, there was a high percentage of missing data. Further crosssectional studies cannot determine causality between the exposure and the outcome; therefore, similar analysis should be undertaken in a longitudinal analysis. Apart from that, the HBsAg status was missing for many patients who were screened in the study period in which we conducted our study. A large number of possible participants dropped from the study. For example, although all the facilities in Lusaka analyzed are large, the number of participants with known HBV status varied widely suggesting uneven uptake of the MoH HBV-screening recommendation. Despite these limitations, we believe that the study has provided some reliable evidence on the association between HIV/HBV co-infection and the levels of CD4 and ALT in HAART naïve patients at baseline. These findings did not appreciably differ from other authors from within the country and elsewhere. This suggests that the study was still epidemiologically sound in its design.
Conclusion
Our study has found that HIV/HBV co-infection is associated with much lower CD4 cell counts and higher ALT than patients who are not co-infected. In patients who were HBsAg positive, CD4 cell count was much lower than in patients who were HBsAg negative. The risk of experiencing elevated ALT was higher in the presence of HBsAg than in its absence, suggesting that HBsAg is related to ALT levels in HIV positive patients. HIV/HBV co-infection can therefore not be ignored.
Recommendations
These findings suggest that HIV/HBV co-infection leads to reduced liver function and possibly
compromised immune system and practitioners should take care when such patients are put on ART treatment to avoid drugs that are associated with hepatotoxicity. These data support Zambian Ministry of Health recommendations that all HIV-infected individuals be screened for HBV and that HBV co-infected patients with liver disease be initiated on ART regardless of CD4 count. Increased efforts should be made in the fight against HBV and in how patients affected are managed.
